Idiopathic Short Stature Clinical Trial
Official title:
A Study of the Genetic Determinants of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short stature with no identifiable medical cause. The purpose of the study is to identify differences in the genetic characteristics of participants who responded well or poorly to growth hormone therapy. No medications or other treatments are provided to the participants by Novo Nordisk as part of this study. The study will last for up to 1 year. The participants will attend their usual doctor's appointments. If the participants are not usually visiting the clinic, they will need to do it only once as part of this study. If the participant agrees to take part in the study, they will be asked to read and sign the 'Agreement to take part form'.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06382155 -
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
|
Phase 2 | |
| Completed |
NCT01246219 -
Short Stature Related Distress
|
Phase 4 | |
| Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
| Completed |
NCT00710307 -
Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
|
||
| Completed |
NCT01504802 -
Pharmacodynamics of CNP During Growth Hormone Treatment
|
N/A | |
| Completed |
NCT01248416 -
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
|
Phase 3 | |
| Completed |
NCT00488124 -
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
|
Phase 2 | |
| Withdrawn |
NCT01438801 -
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
|
Phase 4 | |
| Recruiting |
NCT06309979 -
A Study to Assess Growth in Children With Idiopathic Short Stature
|
||
| Terminated |
NCT00121875 -
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
|
Phase 4 | |
| Not yet recruiting |
NCT05858606 -
Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
|
N/A | |
| Active, not recruiting |
NCT04020913 -
Skeletal Muscle Effects of GH in Boys
|
||
| Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 | |
| Recruiting |
NCT02973061 -
The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
|
||
| Completed |
NCT01778023 -
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
|
Phase 3 | |
| Recruiting |
NCT01604395 -
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
|
||
| Active, not recruiting |
NCT00840944 -
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
|
Phase 4 | |
| Completed |
NCT01070173 -
Ghrelin Levels in Children With Poor Growth
|
N/A | |
| Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
| Recruiting |
NCT04798690 -
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
|